By Khushi Namdev
Marking what could be a breakthrough in the world of cancer care, Russia has recently declared that its cancer vaccine, named Enteromix, is based on technology similar to the COVID-19 mRNA vaccine. As per a Russian news agency, TASS, the vaccine has shown 100 percent efficacy in its preclinical trials.
The shots, which can be tailored for personalized use, have shown significant effect in shrinking and slowing the growth of tumors and have reportedly been found safe for repeated use. The first version of the vaccine has been rolled out to be used against one of the most common colorectal cancers, while there are developments still in progress for aggressive skin and brain cancers in their initial stages.
Instead of using a dead and weakened virus, the mRNA vaccines deliver genetic instructions to the body’s cells. These instructions later on instruct the body’s cells to produce a specific antigen. Once they are recognised, the immune system of the body generates antibodies to target and neutralize them.
The Russian Federal Medical and Biological Agency has announced that the vaccine is ready for use. Also, it has successfully passed its preclinical trials, depicting a great level of security and high effectiveness.
However, the trials were conducted on fewer than 50 people, and therefore, it is crucial to carry out the trial on larger groups to evaluate the therapy’s impact on a wider and more diverse population.
While scientists and medical experts have made several advancements in medicine, cancer is still known as the most feared, expensive, and dangerous disease. Therefore, innovations like these are game-changing because they give hope for survival to patients and their loved ones.